Our Blog Posts

***Please note that the information below was delivered to clients on July 8, 2025.*** On July 9, 2025, a Hearing on the Motion to Stay the Cease-and-Desist Order is currently scheduled to commence at 10:00 AM PT in the Case of: "Sable Offshore Corp et al vs California Coastal Commission" (Case #25CV00974).  Please note that this […]

***Please note that the information below was delivered to clients on May 19, 2025. While we continue to believe that the information below provides a good introduction to the ongoing litigation, it is worth noting that the Court Denied the Motion for a Preliminary Injunction on May 28, 2025.*** On May 30, 2025, a Hearing […]

***Please note that the post below is an excerpt from a larger distribution delivered to clients on September 12, 2023*** On March 7, 2023, the U.S. Department of Justice filed a Case in the District of Massachusetts seeking to enjoin JetBlue Airways Corporation's (JBLU) proposed acquisition of Spirit Airlines Inc. (SAVE) for $3.8 billion.  This is the Case of: "United States of […]

On November 29, 2022, the Bench Trial is scheduled to commence at 9:00 AM PT in the Case of: “Rimini Street, Inc. v. Oracle International Corporation” (Case #14-01699 in the District of Nevada).   This Bench Trial will be limited to Oracle’s claims for Equitable Relief (including Injunctive Relief) and should last between 2 and 3 weeks.  It was […]

On March 28, 2022, the Bench Trial with Judge Andrews began in the Case of: “United Therapeutics Corporation v. Liquidia Technologies, Inc.” (Case Number 20-00755 in the District of Delaware).  The Bench Trial concluded with Closing Arguments on March 31, 2022, and following the conclusion of Post-Trial Briefing, we will then be awaiting the Court's Decision in this […]

A 4-day Bench Trial is currently scheduled to commence on April 25, 2022 at 8:30 AM ET in Eagle Pharmaceuticals' Case related to its BENDEKA® product.  This is in the Case of: "Eagle Pharmaceuticals, Inc. v. Hospira, Inc." (Case #18-01074 in the District of Delaware).  Additionally, the Pretrial Conference in this Case is currently scheduled to be […]

A Hearing on the Order to Show Cause as to why Oak Pacific Investment (“OPI”) should not be restrained from Disposing (or any other related activity) of Social Finance, Inc. (“SoFi”) shares is currently scheduled to be held on Friday, May 14, 2021 at 9:30 AM ET in the Case of: “In Re RenRen, Inc. Derivative […]

On January 15, 2021, the United States Patent & Trademark Office’s (“USPTO”) Patent Trial & Appeal Board (“PTAB”) issued a Decision that DENIED Institution of a Petition for Inter Partes Review filed by Regeneron, Inc. (REGN) against a Patent Owned by Novartis (NVS).  In light of this development, this email provides an overview of Regeneron’s remaining outstanding […]

On December 8, 2020, Telephonic Oral Arguments are currently scheduled to commence at 10:00 AM ET in the Appellate Cases of: “Mylan Pharmaceuticals Inc. v. Biogen MA Inc.” (Case #20-1673 at the Court of Appeals for the Federal Circuit) and “Biogen International GmbH v. Mylan Pharmaceuticals Inc.” (Case #20-1933 at the Court of Appeals for the Federal Circuit).  This […]

On September 2, 2020, the Hearing in Teva’s “Post Grant Review” challenging Corcept’s U.S. Patent Number 10,195,214 (which covers Corcept’s Korlym product) was held before the United States Patent & Trademark Office’s (“USPTO”) Patent Trial & Appeal Board (“PTAB”).  This was in PGR2019-00048, and we now expect the PTAB to issue its Final Written Decision […]